We have a vision to stop disease progression and restore function
- That's why we are unlocking the potential of a new class of drugs

Company in Brief

Vicore is an innovative Swedish clinical-stage pharmaceutical company with a vision to transform the lives of patients where modulation of the AT2 (angiotensin II type 2) receptor can play a central role in halting and reversing disease pathology

Location: Stockholm, Sweden, Cambridge, MA, USA & Copenhagen, Denmark

Employees: ~25 FTEs.

Ticker: VICO, listed at Nasdaq Stockholm

Key shareholders: HealthCap, HBM Healthcare Investments, Orbimed, Suvretta and Invus

Website: www.vicorepharma.com

Management Team

Strong leadership team with extensive industry experience.

Ahmed Mousa*
CEO

Hans Jeppsson
CFO

Bertil Lindmark*
Chief Medical Officer

Johan Raud*
Chief Scientific Officer

Johanna Gräns
Program Director, early development

Jessica Shull*
Director of Digital Health

Nina Carlén
Chief Administrative Officer

Åsa Magnusson*
Chief Engagement and Commercial Officer

Mikael Nygård
VP Operations and Corporate Strategy

Jimmie Hofman*
VP Business Development

Sophie Bertilsson
Interim Head of CMC

Megan Richards
VP Investor Relations, Communications and Portfolio Strategy.

*Attending RIS

Board Members

Hans Schikan
25 years management experience in global pharmaceuticals (CEO of Prosensa & leading roles at Genzyme and Organon). Extensive board work in listed life science companies (Hansa Biopharma, Wilson Tx (acquired by Alexion), SOBI, Asceneuron, InteRNA and Theracho (acquired by Pfizer).

Jacob Gunterberg
Chairman. Former partner at HealthCap with extensive experience from venture capital investment operations and corporate finance in life science. Extensive experience as board member in both private and publicly traded companies.

Heidi Hunter
More than 25 years of experience from leading positions in different roles within pharmaceutical development and commercialization. Leadership experience spans alliance management, investment risk mitigation, global clinical and commercial management, new business strategy development, product launch, and business sustainability.

Ann Barbier
Ann has more than 20 years of drug discovery and development experience in the pharmaceutical and biotech worlds. She has contributed to several approved drugs and has worked in the rare disease, neuropsychiatry and pulmonology fields.

Elisabeth Björk
More than 15 years of experience from clinical practice, academic research and management of drug development in big pharma as well as global commercial strategy and implementation across regions and therapy areas. Currently leading global late-stage development activities in Cardiovascular, Renal & Metabolism at AstraZeneca.

Michael Buschle
More than 25 years of experience in basic research as well as biotech and pharma R&D. Experience at mid-size pharma and biotech companies including in- and out-licensing of assets as well as from C-level positions. Longstanding experience in investment consulting and financing and currently a consultant within the biotech industry for HBM Partners AG.

Yasir Al-Wakeel
Yasir is a seasoned executive, board member, and strategic advisor to biotech companies. He is currently the CEO of a genetic medicines company based in California and serves as an independent board member for Maxcyte. Yasir has had operational experience running finance and business development functions at both public and private biotech companies, and prior to that had senior roles in investment banking both as an equity analyst and in corporate finance.

Buloxibutid (C21) has disease modifying potential by driving lung repair

Buloxibutid is an oral, selective AT2R agonist with multiple beneficial effects on alveolar epithelial type 2 cells (AEC2)



Unprecedented clinical data with buloxibutid in IPF - Phase 2a AIR trial[1,2]

May 2023 Interim Analysis



Final Phase 2a AIR trial data to be presented at ATS 2024 in oral late-breaking presentation

Mini Symposium A18, Sunday May 19, 10:39 AM, Room 8 (Upper Level)

Note: n=46 patients with 2-week data. Observed values, no imputation.

*p<0.05, ** p<0.01, ***p<0.001 FVC scaled to 24 weeks vs change of -120 mL/24 weeks applied to each week (untreated).

Untreated: Expected average decline for untreated patients based on published placebo data [3,4]

References:
[1] Batta R et al. Am J Respir Crit Care Med 2023;207:A2531
[2] Ganslandt C et al. Am J Respir Crit Care Med 2024;209:A1055
[3] Noble et al. Eur Respir J. 2016 Jan; 47(1): 243–253
[4] Richeldi et al. Engl J Med 2014; 370:2071-2082

Advancing a diversified pipeline



Strong preclinical evidence for buloxibutid in pulmonary fibrosis



Fibrosis reduction in humans IPF lung slices (PCLuS)

Dose-dependent reduction of TGFβ1 and Collagen-1a1 protein

Ref: Vicore data on file

Buloxibutid (C21) reduces fibrosis, collagen content and reverses vascular remodeling



Ref: Bruce et al. 2015, Rathinasabapathy et al. 2018, Tomling et al.2023

Vicore – Strong Presence at the ATS 2024 Congress

Buloxibutid (C21) Phase 2b ASPIRE Trial in IPF

- Robust and patient friendly RCT
- 52 weeks
- 270 patients
- Recruiting soon
- Check out our ASPIRE clinical trial booth at ATS (CT6)

ASPIRE

Oral Late-Breaking Presentation

Buloxibutid, a Novel Angiotensin II Type 2 Receptor Agonist, Stabilized and Improved Lung Function in Individuals with Idiopathic Pulmonary Fibrosis in the 36-week Phase 2 AIR Trial

- Mini Symposium A18: Fixing What's Broken: Novel Therapeutics for Lung Remodeling
- Sunday May 19, 10:39 AM, Room 8 (Upper Level)

Poster Presentations

Deciphering the Clinical Efficacy Mechanisms of Buloxibutid in Idiopathic Pulmonary Fibrosis

- Poster Discussion Session B30: Scarred for Life: Translational Research in Interstitial Abnormalities and Lung Fibrosis
- Monday May 20, 9:15 AM, Room 31A-C (Upper Level)

Crafting a Patient-focused Phase 2b Trial (ASPIRE) to Evaluate Efficacy and Safety of Buloxibutid in Individuals with Idiopathic Pulmonary Fibrosis (IPF)

- Thematic Poster Session B48: New Treatments in Diffuse Parenchymal Lung Disease
- Monday May 20, 11:30 AM, Area K (Hall H, Ground Level)

Thank you to patients and their caregivers for supporting our trials. We recognize your contribution to research.



ATS 2024 Respiratory Innovation Summit

vicore pharma